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ABSTRACT
Natural killer (NK) cells are a population of innate type I lymphoid cells essential for early anti-viral
responses and are known to modulate the course of humoral and cellular-mediated T cell responses. We
assessed the role of NK cells in allogeneic CD8 T cell-mediated responses in an immunocompetent
mouse model across an MHC class I histocompatibility barrier to determine its impact in therapeutic
clinical interventions with polyclonal or monoclonal antibodies (mAbs) targeting lymphoid cells in
transplantation. The administration of an NK cell depleting antibody to either CD8 T cell replete or
CD8 T cell-depleted naïve C57BL/6 immunocompetent mice accelerated graft rejection. This accelerated
rejection response was associated with an in vivo increased cytotoxic activity of CD8 T cells against bm1
allogeneic hematopoietic cells and bm1 skin allografts. These findings show that NK cells were impli-
cated in the control host anti-donor cytotoxic responses, likely by competing for common cell growth
factors in both CD8 T cell replete and CD8 T cell-depleted mice, the latter reconstituting in response to
lymphopenia. Our data calls for precaution in solid organ transplantation under tolerogenic protocols
involving extensive depletion of lymphocytes. These pharmacological biologics with depleting proper-
ties over NK cells may accelerate graft rejection and promote aggressive CD8 T cell cytotoxic allore-
sponses refractory to current immunosuppression.
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Introduction
Natural killer (NK) cells are a population of granular lym-
phoid cells phenotypically characterized by expression of
NK1.1 or DX5 and the lack of CD3 and T cell receptor in
C57BL/6 mice (B6 mice).1, 2 These bone marrow-derived
innate cells have evolved to attack and kill viral infected and
transformed cells in a non-MHC restricted manner without
the need of prior sensitization. A balance of signals orche-
strated through inhibitory and activating receptors on NK
cells interacting with MHC class I and non-MHC molecules
expressed on target cells triggers NK cell function. This array
of germline-encoded inhibitory and activating receptors
detects alterations in the molecular composition of the target
cells due to infection, malignant transformation or cellular
stress, instructing NK cells to respond to altered self.1,3–5
NK cells are also very sensitive to changes on MHC class I
expression. Thus, cells expressing MHC class I mismatched
molecules or autologous cells lacking self-MHC class I
molecules or cells in which self-MHC class I molecules are
down-regulated (missing self-theory) become targets for NK
cell-mediated cytolysis.5–7 Moreover, lethally irradiated F1
hybrid mice spontaneously reject parental bone marrow cells
(BMCs) or hematopoietic cells, a phenomenon against the
laws of transplantation named “hybrid resistance”, first
described by Snell et al., and then confirmed by others.8–11
Compelling evidence points to NK cells as regulators of both
humoral and cellular immune responses in viral infections. In
different experimental settings, antibody-mediated NK cell
depletion modulates the course of CD8 T cell responses by
increasing CD8 T cell priming in the acute phase of viral
infection and enhancing memory responses characterized by
an increase of central memory T cells (CD44hi CCR7+
CD62L+).12,13 Similarly, depletion of NK cells leads to
increased numbers of T follicular helper cells (Tfh) and germ-
inal center B cells, resulting in more sustained antibody
responses after acute and chronic viral infections.14,15
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The role of NK cells in transplant rejection and tolerance is
controversial and paradoxical, meaning that they can promote
either rejection or tolerance. NK cells reject allogeneic bone
marrow cells2,16 and participate in the rejection of solid
organs.17 NK cells also promote cardiac allograft vasculopathy
(CAV) when parental heart grafts are placed into F1 recipi-
ents, in which NK cells are the only active mechanism of
rejection.18 NK cells may also contribute to prolong graft
survival and transplant tolerance by eliminating donor-
derived antigen-presenting cells (APC) and limiting the direct
pathway of antigen presentation and T cell priming in drain-
ing lymph nodes.19,20
NK cells can also modulate CD8 T cell-mediated graft
rejection downregulating CD8 T cell homeostatic prolifera-
tion in response to lymphopenia by competing for common
growth factors, such as interleukin (IL)-15.21 Moreover, the
population of NK cells expressing low rather than high levels
of CD27 has been shown to promote allograft survival by
limiting the homeostatic proliferation and expansion of inter-
feron-γ–producing memory CD8+ T cells under costimula-
tory blockade.22
In this study, our aim was to address whether NK cells
could modulate CD8 T cell-mediated response in an immu-
nocompetent mouse model of alloreactivity across an MHC
class I barrier in which rejection is mainly mediated by CD8 T
cells and determine its effect in therapeutic interventions
involving depletion of NK and/or CD8 T cells.23–25 Herein,
we provide evidence that the removal of NK cells (CD3−DX5+
population and within this, the DX5+NKp46+ subpopulation)
accelerated skin graft rejection in immunocompetent B6 reci-
pients in both CD8 T cell replete and CD8 T cell-depleted
recipients. These findings revealed that NK cells regulate
allogeneic CD8 T cell responses to skin allografts when sti-
mulated through the direct pathway of antigen presentation
not only in immunocompetent recipients, but also in CD8 T
cell-depleted recipients.
Results
Naïve NK cells regulate CD8 T cell-mediated rejection of
allogeneic hematopoietic target cells in vivo in
immunocompetent recipients
To determine whether NK cells regulate the course of graft rejec-
tion in immunocompetentmice, we chose an experimentalmouse
model in which donor and recipient differed in Kb allele (bm1
donor to B6 recipient).26 In this transplant setting, alloreactive
effector CD8 T cells activated through the direct pathway of
antigen presentation are the main mediators of rejection.23
In order to confirm the role of CD8 T cells in targeting
bm1 alloantigen, carboxyfluorescein succinimidyl ester
(CFSE)-labeled bm1 splenocytes were adoptively transferred
intravenously (i.v.) into B6 recipients that were depleted of
either NK cells or CD8 T cells. In un-manipulated hosts, there
was a gradual clearance of donor bm1 cells (Figure 1); how-
ever, in mice depleted of CD8 T cells no cytolytic activity
against bm1 target cells was observed 5 days post-transfer
(Figure 1). The cytotoxic activity in this group eventually
began to recover in both spleen (Figure 1A) and in peripheral
lymph nodes (pLNs) (Figure 1B), which was likely due to the
declining antibody concentration in the periphery and recon-
stitution of the CD8 T cell compartment through thymic
output and peripheral homeostatic proliferation in response
to lymphopenia. Interestingly, the depletion of NK cells led to
an increased clearance of CFSE-labeled bm1 cells at day 5
after adoptive transfer compared to isotype-treated control in
spleen and pLNs (Figure 1) such that bm1 cells were practi-
cally undetectable by day 15 in either spleen (Figure 1A) or
pLNs (Figure 1B).
Taken together, these data confirm that CD8 T cells are the
major immune cell population involved in the recognition
and clearance of cells bearing the Kbm1 alloantigen in this
setting. Furthermore, consistent with other studies, NK cells
appeared to hamper cytotoxic T lymphocyte (CTL)-mediated
clearance of bm1 cells, suggesting a role for NK cells in
modulating CD8 T cell responses to alloantigen. These find-
ings prompted us to analyze in more detail the role of NK
cells in a more relevant mouse model of skin allotransplanta-
tion across an MHC class I mismatched barrier in immuno-
competent recipients.
NK cell depletion accelerates skin graft rejection across
an MHC class I histocompatibility barrier in
immunocompetent mice
We designed an experimental approach to evaluate the rele-
vance of the above mentioned observations and to assess the
outcome of skin graft survival in the context of immunosup-
pressive depleting regimens targeting either CD8 or NK cells.
This reflects a particular scenario of clinical interventions
such as, for example, immunosuppressive regimens based on
thymoglobulin or anti-CD52 antibody therapy (alemtuzumab)
with depleting activity on lymphoid cells.27,28
As shown in Figure 2A, depletion of NK cells at the time of
transplantation accelerated bm1 skin graft rejection in B6
recipients (median survival time (MST): 12 days) compared
to isotype-treated controls (MST: 15 days) (p < 0.0001). This
suggests that NK cells regulate CD8 T cell-mediated rejection
in immunocompetent recipient mice. Interestingly, depletion
of NK cells together with CD8 T cells also significantly accel-
erated bm1 skin graft rejection in B6 immunocompetent
recipients compared to CD8 T cell-depleted B6 recipients
(MST: 20 days versus 26 days, p < 0.0001) (Figure 2B).
Figures 2C and 2D show representative macroscopic and
microscopic photographs of skin bm1 allografts at day 13 and
day 21 post-transplantation (post-Tx, respectively. Bm1 skin allo-
grafts transplanted to B6 recipients were rejected with an MST of
12 days in NK cell-depleted mice whereas bm1 grafts remained
intact in isotype control-treated mice at this time, although they
were eventually rejected (MST: day 15 post-Tx). Macroscopic
signs of rejection and histopathological lesions were clearly detect-
able in NK cell-depleted recipients and in anti-NK1.1 plus anti-
CD8 T cell-depleted B6 mice, at days 13 and day 21 post-trans-
plantation, respectively (Figures 2C and 2D).
Moreover, our work confirms previous evidences support-
ing the lack of alloantibody response against H-2Kbm1 class I
conformational epitopes in C57BL/6 recipients,23 as either no
detectable Tfh expansion (CD4+CXCR5+PD-1+) cells or
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germinal center formation (B220+GL7+Fas+) or host anti-
donor humoral response was seen, as shown in supplementary
Figure 1.
Overall, the data indicate that naïve or homeostatically
dividing NK cells regulate the alloreactive cytotoxic response
of CD8 T cells in CD8 T cell replete and CD8 T cell-depleted
mice, respectively.
NKT cell and NK cell expansion in draining lymph nodes is
associated with ongoing alloreactive CD8 T cell-mediated
responses and graft rejection
We first monitored the effectiveness of the depleting NK cell
therapy at day 13 and day 21 post-Tx, which corresponded with
the time points around which rejection occurred in NK cell-
depleted and in CD8/NK1.1 cell-depleted B6 mice, respectively.
The population of NKT cells (DX5+ CD3+), a priori susceptible to
depletion by anti-NK1.1 antibody, did not show any significant
reduction in cell number compared to isotype-treated control
group in either draining or non-draining lymph nodes at any of
the two time points evaluated (day 13 post-Tx, Figure 3, upper left
panel and day 21 post-Tx, Figure 3, upper right panel). It is
noteworthy that NKT cells increased significantly in draining
compared to non-draining pLNs at day 13 post-Tx in isotype-
treated mice close to rejection and in NK cell-depleted mice
undergoing rejection, respectively (Figure 3, upper left panel).
There was also a significant increase in NKT cell numbers at day
21 post-Tx in CD8 T cell-depleted mice near the time of rejection
and in CD8/NK1.1 cell-depleted mice undergoing rejection
(Figure 3, upper right panel). However, there was no significant
difference in the number of NKT cells between treatment groups
in either non-draining or draining pLNs at day 13 and day 21 after
Tx (Figure 3, upper left and right panels). These data show that
NKT cells expand in the draining pLNs during graft rejection.
NK cells (DX5+ CD3−) exhibited a significant reduction in cell
numbers in draining pLNs after depletion with anti-NK1.1 mAb
compared to isotype control at day 13 and day 21 post-Tx, but did
not completely eliminate this cell population (Figure 3, middle left
Figure 1. Host NK cells regulate CD8 T cell-mediated cytotoxic responses in vivo against bm1 hematopoietic target cells.
Naïve B6 mice were treated at day 0 and day 7 with 1 mg/mouse of isotype control (red bars), anti-NK1.1 antibody (black bars) or anti-CD8 antibody (blue bars). The
same day, the three groups of mice were injected with CFSE-labeled female bm1 splenocytes (15 × 106 splenocytes). The absolute number of bm1 hematopoietic
cells remaining in spleen and peripheral lymph nodes (pLNs) (inguinal plus axillary and brachial) was evaluated at day 5, 9 and 15 after cell transfer. Results are
expressed as mean ± SD and the data comes from a pool of two experiments with three mice per experimental group.*, p < 0.05; **, p < 0.005; ***, p < 0.0005 were
considered statistically significant.
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and right panels). The most sensitive NK cell population to anti-
body-mediated depletion was, however, the NK cell population
co-expressing DX5 and NKp46 surface markers. Once eliminated
from the periphery at day 13 post-Tx (Figure 3, lower left panel),
the rate of repopulationwas slow and the absolute counts were still
profoundly reduced at day 21 post-Tx (Figure 3, lower right
panel).
Both subsets of NK cells (DX5+CD3− and DX5+NKp46+)
expanded in draining compared to non-draining pLNs in
isotype-treated control at day 13 after transplantation. NK
cell numbers also increased significantly, probably as a result
of active proliferation or recruitment in draining compared to
non-draining pLNs at day 13 and day 21 post–Tx in CD8 T
cell-depleted mice (Figure 3, middle and lower left and right
panels) Furthermore, the number of NK cells was increased in
the draining pLNs of CD8 T cell-depleted mice compared to
the isotype-treated group at both day 13 post-Tx (Figure 3,
middle and lower left panels) and at day 21 post-Tx (Figure 3,
middle and lower right panels).
Our data highlighted that NK cells increased in cell num-
bers after CD8 T cell depletion, taking advantage of the open
space left by CD8 T cells, preferentially in draining pLNs
where the allogeneic immune response is occurring.
Globally, these findings are in favor of the notion that NK
cells compete with CD8 T cells for space in pLNs and exploit
their niche. Moreover, NK cells, and in particular NKp46
expressing cells, represent the most likely effector innate
cells involved in the regulation of allogeneic CD8 T cell-
mediated responses stimulated through the direct pathway
of antigen presentation.
Effective CD8 T cell depletion and CD4 and CD8
peripheral expansion of naïve and memory type T cells in
draining lymph nodes
We next evaluated the effectiveness of CD8 T cell-specific deple-
tion with anti-CD8 mAb treatment.29 This depleting therapy was
very effective because the absolute cell counts dropped profoundly
after the administration of two doses of anti-CD8 depleting anti-
body, as assessed in draining and non-draining lymph nodes at
day 13 post-Tx (Figure 4, upper left panel). The absolute counts of
CD8 T cells were still very low at day 21 post-Tx (Figure 4, upper
right panel), although an incipient recovery was already detectable
at that time point, which was significantly higher in draining than
in non-draining pLNs. Despite the low number of CD8 T cells
Figure 2. Depletion of NK cells accelerates bm1 skin allograft rejection in both CD8 T cell replete and CD8 T cell-depleted B6 recipients.bm1 skin allografts placed on
B6 recipients were followed for 40 days after transplantation. C57BL/6 recipient mice were treated at day 0 and day 7 with 1 mg of either isotype control or anti-
NK1.1 depleting antibody (A), or with anti-CD8 mAb or anti-CD8 mAb plus anti-NK1.1 mAb (B). The survival curve was plotted following the Kaplan–Meier life table
method and the statistical analysis was performed using the long-rank test. The survival curve is the global result of a pool of 6 experiments. Visual macroscopic
inspection of the bm1 skin grafts (C) and hematoxylin and eosin (H/E) staining of skin tissue sections (D) of the four experimental groups are depicted at day 13 and
day 21 post-Tx. bm1 skin graft rejection occurred at day 13 post-Tx in NK cell depleted recipients and at day 21 post-Tx in CD8/NK cell depleted recipients few days in
advance than in isotype control or anti-CD8 T cell depleted mice, respectively. Severe rejection of donor bm1 tail skin was accompanied with necrosis of donor
epithelium and intense dermal mononuclear infiltration. Black dotted ellipse highlights massive necrosis of skin epithelium and dermis underneath of donor bm1 skin
graft in the tissue section. Statistical significance is indicated as follows: *p < 0.05, **p < 0.005, ***p < 0.0005, and ns, non-significant.
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observed at day 21 post-Tx, the frequency of alloreactive cells
recognizing bm1 histoincompatible antigens was sufficient to
initiate skin graft rejection in NK/CD8 cell-depleted B6 mice
(Figure 2B), whereas the presence of NK cells delayed rejection
of bm1 skin grafts in CD8 T cell-depleted mice (Figure 2B).
A significant peripheral expansion of CD8 T cells was
found in draining compared to non-draining pLNs in iso-
type-treated and anti-NK1.1-treated groups at day 13 post-Tx
(Figure 4, upper left panel). CD8 T cells also expanded sig-
nificantly at day 21 post-Tx in draining compared to non-
draining pLNs in CD8 T cell-depleted and CD8/NK1.1 cell-
depleted mice (Figure 4, upper right panel).
We then analyzed the peripheral clonal expansion of CD4 T
cells in non-draining versus draining pLNs. We included CD4 T
cells in the analysis despite the fact that CD4 T cell depletion
alone does not change the course of allograft rejection in this
mouse model. However, it is known that depletion of CD4 T
cells synergizes with depletion of CD8 T cells and prolongs graft
survival beyond that observed in CD8 T cell-depleted mice, a
clear indication that CD4/CD8 T cell collaboration is necessary
to a certain extent for effective CD8 T cell-mediated rejection in
this model.23,24 The absolute number of CD4 T cells increased in
draining pLNs of all experimental groups compared to non-
draining pLNs at day 13 post-Tx (Figure 4, lower left panel).
CD4 T cells also expanded significantly after CD8 T cell deple-
tion or in CD8/NK1.1 cell depleted mice (Figure 4, right panel).
These observations suggest that CD4 T cells were also active
during graft rejection in draining pLNs of rejecting mice.
To assess the effect of NK cell depletion on the adaptive
immune response to skin allografts, the number of
alloreactive CD4 and CD8 effector and central memory T
cells was determined. A significant increase in the number
of CD4 and CD8 T effector memory (TEM, CD44high
CD62Llow) and T central memory (TCM, CD44high
CD62Lhigh) cells in isotype and anti-NK1.1-treated mice was
observed at day 13 post-Tx in draining pLNs compared to
non-draining pLNs (Figure 5A). Alloreactive CD4 T cells and
CD8 T cells as well as TEM and TCM cells counts increased
significantly in draining compared to non-draining pLNs in
isotype and NK1.1-treated groups at day 13 post-Tx and also
in CD8 and CD8/NK cell depleted recipient at day 21 post-Tx
(Figure 5A, 5B).
This peripheral increase of CD4 and CD8 TEM and TCM cell
numbers suggest an active process of clonal expansion of both
cell populations in response to donor bm1 antigens and T cell
differentiation towards memory cells with cytotoxic function.
Enhanced in vivo cytotoxic activity against bm1 target
cells after NK cell depletion in naïve immunocompetent
mice and in CD8 T cell-depleted recipients after skin graft
rejection.
To evaluate the degree of sensitization of B6 recipients after
exposure to allogeneic bm1 skin grafts at the time of rejection,
an in vivo cytotoxic assay was implemented. Thus, at day 13
post-Tx, NK cell-depleted B6 recipients efficiently killed
CFSE-labeled allogeneic bm1 splenocytes in the spleen in
24 hours, whereas the other groups did not exhibit any
remarkable cytotoxic activity (Figure 6A, upper left panel).
In the peripheral lymph nodes, however, isotype-treated
Figure 2. (Continued).
1034 J. I. RODRIGUEZ-BARBOSA ET AL.
Figure 3. NKT cell and NK cell expansion in draining pLNs during the course of graft rejection in both CD8 T cell replete and CD8 T cell-depleted recipients.
Non-draining and draining axillary and brachial pLN from each experimental group of bm1 skin-grafted B6 recipients were collected at two time points after
transplantation. The absolute number of NKT (DX5+CD3+) cells, non-T NK cells (DX5+CD3− cells and DX5+NKp46+ cells) was quantified at day 13 (left side
panel) and day 21 (right side panel) post-Tx. Results are displayed as mean ± SD. Statistical significance and p value was calculated using unpaired Student’s t
test for the comparison of means between draining versus non-draining pLN in each experimental group. One way ANOVA was applied for the comparison of
means among experimental groups within non-draining or draining pLNs. The following criterion of statistical significance was used: *, p < 0.05; **, p < 0.005;
***, p < 0.0005. These plots display data pooled from three independent experiments with three mice per group.
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control mice showed evidence of presensitization and cyto-
toxic activity to some extent, although they rejected a few days
later (Figure 6A, upper right panel).
At day 21 post-Tx, NK/CD8 cell-depleted B6 recipients
showed strong sensitization with high cytotoxic activity
against bm1 target cells in spleen compared to CD8 T cell-
depleted B6 mice (Figure 6B, lower left panel). Some residual
cytotoxic activity was still present in sensitized isotype-treated
B6 mice and NK cell-depleted mice that had already rejected
their grafts two weeks previously. This observed cytotoxic
activity in the spleen was similar and correlated well to that
recorded in peripheral lymph nodes (Figure 6B, lower right
panel).
We performed an experiment at the early time point after
bm1 skin grafting to assess the frequency of bm1 antigen
specific CD8 T cells in draining compared to non-draining
lymph nodes using the CD107a degranulation assay.30
Depletion of NK cells led to a modest increase of the fre-
quency of CD8 T cells expressing CD107a responding to
alloantigen compared to isotype-treated mice. This slight
Figure 4. Expansion of CD4 T cells and CD8 T cells in draining pLNs of B6 mice after skin transplantation across an MHC class I barrier.
Non-draining and draining axillary and brachial pLNs from each experimental group of bm1-skin grafted B6 recipients were collected at two time points after
transplantation.The absolute number of CD8 T cells (upper panels) and the absolute number of CD4 T cells (lower panels) at day 13 and day 21 post-Tx is depicted in
draining and non-draining lymph nodes. Results are displayed as mean ± SD. Statistical significance and p value was calculated using unpaired Student’s t test for the
comparison of means between draining versus non-draining pLN in each experimental group. The following criterion of statistical significance was used: *, p < 0.05;
**, p < 0.005; ***, p < 0.0005. These plots display data pooled from three independent experiments with three mice per group.
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increase in CD8+CD107a+ T cells detected in draining lymph
nodes is in line with the claim of a low frequency of T cells
responding to bm1 antigens (Figure 7).
Globally, these data reinforce the notion that NK cells
modulate CD8 T cell cytotoxic responses against class I
MHC mismatched target cells because, in their absence, cyto-
toxic responses were more aggressive.
Discussion
The purpose of this work was to assess the role of host NK
cells in the regulation of CD8 T cell mediated responses
stimulated through the direct pathway of antigen
presentation.23–25,31 In this mouse model, alloreactive host
CD8 T cells recognize directly unprocessed MHC class I
mismatched Kbm1 antigen, whereas alloreactive host CD4 T
cells are activated by donor and host dendritic cells (DCs)
that shared MHC class II presenting donor Kbm1-derived
peptides through the indirect pathway of antigen
presentation.25 The frequency of alloreactive CD4 T cells
recognizing allogeneic peptides is very low, which is trans-
lated into limited IL-2 help to alloreactive CD8 T cells.31
bm1-specific CD4+ T helper cells can see a peptide derived
from the Kbm1 molecule encompassing the three mutations
when presented by MHC class II molecules on donor/host
APCs. Despite this low frequency of alloreactive CD4 T
cells, they can synergize with alloreactive CD8 T cells con-
tributing to some extent to the process of rejection across
an MHC class I mismatched barrier.23,24,31 In this
experimental approach, the host anti-donor humoral
immune response against bm1 alloantigens does not con-
tribute to the rejection response because MHC class I Kbm1
in B6 mice does not trigger an alloantibody response. This
was in line with an absolute lack of germinal center forma-
tion and CD4 Tfh cell expansion observed in this setting
(supplementary Figure 1).
Herein, we provide evidence that innate NK cells play an
essential role in delaying CD8 T cell alloreactive responses as
depletion of NK cells accelerates bm1 skin graft rejection in
CD8 T cell replete and in CD8 T cell-depleted B6 immuno-
competent mice.
This immune regulatory behavior of NK cells controlling
CD8 T cell-mediated immunity may have evolved to prevent
aggressive cytolytic responses against infected cells in the
acute phase of viral infection to attenuate excessive tissue
damage and the subsequent immunopathology. Most of the
preliminary evidence on the role of NK cells regulating anti-
viral CD8 T cell responses come from the LCMV model in
which using different strains of virus and dosing, it is pos-
sible to recreate models of acute infection and chronic
infection.32,33 NK cells can directly target CD8 T cells for
elimination in a perforin- NKG2D-dependent manner or
indirectly through the removal of mature DCs or viral-
infected APCs, thus limiting costimulatory signals leading
to attenuation of CD4 T cell help to CD8 T cells.34 In the
absence of NK cells, viral infection triggers CD8 T cell
priming that enhances memory T cell responses, leading to
an increase of the frequency of antigen-specific T cells. T cell
Figure 5. Increased of CD8 T cells and CD4 memory type T cell numbers in draining pLNs of B6 mice after skin transplantation across an MHC class I barrier.The
absolute number of CD8 and CD4 TEM cells at day 13 post-Tx (upper left panel) (A) and day 21 post-Tx (upper right panel) (B) and the absolute number of CD8 and
CD4 TCM cells at day 13 post-Tx (lower left panel) (A) and day 21 post-Tx (lower right panel) (B) is depicted in non-draining and draining lymph nodes. Results are
displayed as mean ± SD. Statistical significance and p value was calculated using unpaired Student’s t test for the comparison of means between draining versus
non-draining pLN in each experimental group. The following criterion of statistical significance was used: *, p < 0.05; **, p < 0.005; ***, p < 0.0005. These plots
display data pooled from two independent experiments.
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differentiation is biased towards central memory T cells.13
NK cells can act as rheostats, regulating CD4 T cell help to
anti-viral CD8 T cells for the control of viral persistence and
the fatal consequences of an intense acute immune
response to viral infection, preventing the associated
immunopathology.35
Figure 6. NK cell depletion augmented in vivo CTL activity of skin-grafted sensitized allogeneic CD8 T cells against bm1 hematopoietic target cells.bm1 skin-grafted B6
recipients were challenged with CFSE-labeled target bm1 cells at day 13 (time of rejection for NK cell-depleted group) and day 21 (time of rejection for CD8/NK cell-depleted
group) after Tx. The killing of bm1 hematopoietic target cells was evaluated as the total cell counts of bm1 cells remaining in spleen (A) and pLNs (B) 24 hours after i.v.
injection of 15 × 106 of CFSE-labeled bm1 target splenocytes at day 13 and day 21 after Tx. Results are displayed from one representative experiment out of two with three
mice for each experimental group. Results are displayed as mean ± SD. *, p < 0.05; **, p < 0.005; ***, p < 0.0005 were considered statistically significant.
Figure 7. NK cell depletion increases donor alloantigen specific CD8+ T cells expressing CD107a.At the time of rejection initiation in NK-cell depleted mice, 1.5 × 105
cells from non-draining and draining pLNs (axillar and brachial) were isolated from syngeneic or allogeneic bm1 skin grafted treated either with isotype control or
anti-NK1.1 antibody. Then, syngeneic and allogeneic lymphocytes were re-stimulated in vitro with 0.5 × 105 allogeneic syngeneic control and bm1 allogeneic mature
BM-DC per well for 1 hour in the presence of PE-conjugated isotype control or PE-conjugated anti-CD107a mAb. Finally, the Golgi plug monensin was added and
incubated 4 more hours. This figure is a representative experiment of two performed with similar results using one mouse/experimental group/experiment.
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In the field of transplantation, previous reports have pro-
vided some preliminary evidences on the modulatory role of
NK cells in allogeneic CD8 T cell responses. Zecher et al.
showed that the adoptive transfer of syngeneic T cell-enriched
splenocytes into immunodeficient Rag2 gamma chain KO
(NK cell deficient) recipients repopulate the peripheral
CD8 T compartment quicker and 8-fold more CD8 T cells
were recovered compared to Rag KO (NK cell sufficient)
recipients. Similar results were observed in wild type mice
depleted of both CD4/CD8 T cells compared to NK/T-cell
depleted WT mice.21 As opposed to Zecher et al., we could
not prove that the removal of NK cells conferred an advantage
to CD8 T cells to recover quicker and to a greater extent. In
our transplant setting, CD8 T cells recovered after depletion
to the same extent in NK sufficient as in NK-cell depleted
mice, meaning that NK cell depletion did not alter the recov-
ery of the total CD8 T cell numbers. Instead, NK cells
exploited the CD8 T cell niche and expanded at day 21
post-Tx intensively in non-draining and draining lymph
node, particularly in CD8 T cell-depleted mice. Interestingly,
NK cells also expanded significantly at day 13 post-Tx in
draining pLNs of isotype-treated control despite the presence
of normal CD8 T cell numbers.
To reconcile these results and to account for the quicker
recovery of CD8 T cells in immunodeficient Rag 2 KO mice
and also in CD4 and CD8 T cell-depleted immunocompetent
recipients, one can postulate that CD8 T cells recovering
under homeostatic conditions in response to lymphopenia
repopulate a peripheral compartment in which CD4 T cells
were also depleted, whereas in our experiments, the CD4 T
cell compartment was intact. It is known that, in the absence
of either CD4 or CD8 T cells subpopulations, the open niche
left by one population can be occupied by the other popula-
tion and vice versa in such a manner that the total number of
T cells remains similar to that present in normal mice. In
other words, these two T cell populations share common
resources and can partially invade each other’s niches. Cell
loss of one cell type can be compensated by the other
population.36,37
For the interpretation of our observations, we should con-
sider two distinct scenarios because MHC class I mismatched
skin grafts are rejected in our experimental setting in two
different situations: CD8 T cell sufficient and CD8 T cell-
depleted recipients undergoing homeostatic CD8 T cell
repopulation.
In CD8 T cell sufficient mice, at day 13 post-Tx, the
mechanism of action of NK cells may be mediated through
the elimination of donor-derived DCs migrating to draining
lymph nodes. This effect would lead to attenuation of the
direct pathway of antigen presentation as shown by
others.19,20,38 Yu et al., compared alloantigen-driven T cell
homeostatic proliferation in lymphopenic environments of
immunodeficient mice after allogeneic skin graft transplanta-
tion between Rag2 deficient (NK sufficient) and Rag2/gamma
chain double-deficient (NK deficient) mice adoptively trans-
ferred with syngeneic T cells. These authors found that defi-
ciency in NK cells increased T cell proliferation and
accelerated allograft rejection, whereas in NK cell sufficient
mice, NK cells induced their immunomodulatory function by
killing donor-derived dendritic cells that migrated to second-
ary lymphoid organs, leading to enhanced allograft survival.19
These findings are coincident with those reported by Laffont
et al., who also provided evidence for the role of NK cells
recruited to the draining lymph nodes in the inhibition of the
alloreactive T-cell activation through a perforin-mediated kill-
ing of donor-derived allogeneic dendritic cells.20
In CD8 T cell-depleted mice undergoing homeostatic T cell
repopulation, at day 21 post-Tx, the role of donor derived DC
is likely to be negligible because of the gradual decay of this
passenger leukocyte population from the graft. In this sce-
nario, NK cells may delay CD8 T cell-mediated rejection for
their ability to compete with the alloreactive CD8 T cells
dividing in recipients devoid of CD8 T cells. In favor of this
notion is that NK cells expanded in draining pLNs of CD8 T
cell-depleted recipients at that time point, competing with the
alloreactive CD8 T cells proliferating in response to bm1
alloantigens and homeostatically to lymphopenia, as well as
with other T cells of the non-alloreactive repertoire. NK cells
and CD8 T cells respond to similar cytokines (IL-2 and IL-15)
for peripheral expansion, and therefore cross-competition for
these common resources cross-regulate the ability of each
population to survive, differentiate and proliferate homeosta-
tically in response to lymphopenia.39–41
Newly generated cells (recent thymic emigrants and per-
ipheral cell division) compete in the immune system with
resident cells for survival.36 Sometimes one population pre-
vents other population from occupying a particular niche and
from exploiting the resources there (interference competi-
tion). In other occasions, and more often, different
populations may have common needs for resources present
in the niche, which is in limited supply (exploitation
competition).36 The CD8 T cell independent niche can, how-
ever, be invaded by other cells, such as NK cells, an example
of exploitation competition, which is in agreement with our
results. This NK cell exploitation of the CD8 T cell niche may
account for the delay of graft rejection. Our data in this sense
is in agreement with that reported by Zecher´s work using
immunodeficient and T cell-depleted immunocompetent reci-
pients who provided evidence in favor of the role of NK cells
in modulating CD8 T cell responses, not by killing home-
ostatically proliferating T cells, but by competing for T cell
growth factors.21 Our findings suggest that this competition
for common resources may provide an advantage to NK cells
that would reduce the availability of these cytokines to the
alloreactive repertoire of CD8 T cell reacting against bm1
antigens. Therefore, reaching the threshold frequency of
alloantigen specific CD8 T cells necessary to initiate rejection
would take longer and consequently graft rejection would be
delayed.
An alternative means for the control of CD8 T cell
responses is the direct killing of activated CD8 T cells upon
upregulation of NKG2D ligands 24–48 hours. Rabinovich
et al. proved that syngeneic IL-2 activated NK cells can detect
altered self-structures on activated CD8 T cells, not present in
resting T cells. These changes in the molecular composition of
activated CD8 T cells make them susceptible to NK cell-
mediated killing by a NKG2D- and perforin-dependent
mechanism.42
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This in vitro NK cytolytic activity is unlikely to occur in vivo
because there are mechanisms of shielding T cells to prevent
their destruction by NK cells, as demonstrated on activated
CD4 T cells expressing Qa-1 that interact with inhibitory
NKG2A NK receptor. This interaction confers CD4 T cells
with resistance to NK cell-mediated lysis.43 Another example
of this shielding applies also to CD8 T cells expressing CD48
that inhibit NK cells through interaction with 2B4 (CD244).44,45
We found no evidence that NK cells were regulating the size of
the CD8 T cell pool, as shown in Figure 4A, by killing activated
alloreactive CD8 T cells because CD8 T cell counts were not
affected in the absence of NK cells.
Conversion from naïve to memory T cell phenotype occurs
in response to rapid homeostatic T cell proliferation in immu-
nodeficient mice adoptively transferred with syngeneic sple-
nocytes or in T cell-depleted immunocompetent recipients.46
Homeostatic proliferation in response to lymphopenia is dri-
ven by TCR interaction with peptide-MHC on APCs and
cytokines, such as IL-7 and IL-15.47 We found that the allor-
eactive CD8 T cell response in draining pLNs was associated
with a significant conversion of naïve to memory type cells
(central memory and effector memory) and increased prolif-
eration in both CD8 T cell replete (only responding to bm1
antigens at day 13 post-Tx) and CD8 T cell depleted mice
(responding to bm1 antigens and to lymphopenia at day 21
post-Tx). NK cell depletion did not modify significantly the
rate of conversion or memory type cell counts.
Although a priori unexpected, no significant changes were
seen in CD8 T cell numbers in the draining lymph nodes of
grafts undergoing rejection. To account for this, one possibility is
that depletion of NK cells led to only a modest increase of the
frequency of CD8 T cells expressing CD107a responding to
alloantigen compared to isotype-treated mice, and this subtle
change was not reflected in the total CD8T cell counts. Secondly,
the time point at which the experiment was analyzed coincided
with the initiation of graft rejection and part of the antigen-
specific response may have already become effector and
migrated to the graft as effector CTLs.
One caveat from the use of anti-NK1.1 antibody for NK cell
depletion is that it may also deplete NKT cells. Therefore, modula-
tion of the immune response after administering anti-NK1.1mAb
might be assigned in part to depletion of NKT cells, which are also
known to exhibit immunoregulatory functions. However, we
showed that NKT cells were not reduced upon anti-NK1.1 anti-
body administration, which supports a role for NK and not NKT
cells in modulating rejection in this setting. NKT cell may have
persisted despite anti-NK1.1mAb administration owing to a rapid
recovery through thymic output or peripheral reconstitution or
because decreased susceptibility to depletion attributable to the
fact that NKT cells express intermediate levels of NK1.1 receptor.
This result is in agreement with a report using a transgenic mouse
model expressing constitutively soluble anti-NK1.1 antibody
(clone PK136). In this mouse model, NK cells were efficiently
eliminated, whereas NKT cell numbers were maintained and not
affected by the chronic presence of the antibody.48
The DX5+CD3− population of NK cells also exhibited
resistance to depletion to some degree because anti-NK1.1
depleting therapy did not achieve complete elimination of
this population in pLNs. The resistance of NK cells
(DX5+CD3−) as opposed to the susceptibility of NKp46 cells
to depletion makes more likely that the latter is endowed with
the capacity to modulate CD8 T cell-mediated allogeneic
responses in this model. However, both NKp46 cells as well
as NK cells (DX5+CD3−) exhibited a competitive advantage
over CD8 T cells and exploited the CD8 T cell niche when
proliferating in draining pLNs, particularly in CD8 T cell-
depleted recipients in the close proximity to rejection.
Evidence supporting a role for NKT cells in allograft rejec-
tion is scarce, with most reports relating to their ability to
support the induction of tolerance.49 This NKT cell activation,
along with proinflammatory molecules secreted during graft
rejection, may enhance their functional activity in such a
manner that can provide an alternative source of help to the
rejection process, particularly when the major effector T cells,
that is, CD8 T cells, are depleted. Similarly to NK cells, NKT
cells expanded significantly in CD8 replete and CD8 depleted
in NK sufficient mice in close proximity to rejection. The
association of NKT cell expansion with ongoing rejection
favors the notion that these cells may also play a role helping
alloreactive CD8 T cells to compensate for their low fre-
quency, which is insufficient for the initiation of graft rejec-
tion. Indeed, according to some reports NKT cells represent
potent helper cells for DC-dependent CTL priming.50
The simultaneous depletion of NK cells and T cells may be
undesirable in transplant recipients because of homeostatic divi-
sion in response to lymphopenia converts the naïve phenotype of
T cells into memory-like phenotype.46 These T cells repopulating
the peripheral compartment precipitate allograft rejection and
resist protocols for tolerance induction.51 Our data calls for pre-
caution in solid organ transplantation under tolerogenic protocols
involving extensive depletion of lymphocytes or leukocytes with
agents such as ATG or alemtuzumab (anti-CD52 mAb) with
partial depleting properties over NK cells. The global immu-
notherapeutic interventions, particularly with polyclonal antibo-
dies against lymphoid cells that target NK cells secondarily, may
accelerate graft rejection and promote aggressive CD8 T cell
cytotoxic responses when proliferating in response to lymphope-
nia because these emergingT cells proliferating under homeostatic
conditions are refractory to current immunosuppression.
Material and methods
Mice
Eight- to 12-week-old female C57BL-6J (B6, H-2Kb, Janvier
Labs) and B6.C-H-2bm1-By mice (H2-Kbm1, hereafter bm1
mice) were bred in our facility and used for the experiments
described in this work. The Animal Welfare Committee of the
University of Alcala de Henares (Madrid) in accordance with
the European Guidelines for Animal Care and Use of
Laboratory Animals approved all experiments with rodents.
Antibodies for in vivo use
Hybridoma cell lines secreting anti-NK.1.1 (clone PK136,
mouse IgG2a) or anti-CD8 (clone 2.43, rat IgG2b) mAbs
were grown in serum-free medium (SFM) (Thermo Fisher
Scientific) supplemented with IgG-depleted fetal calf serum
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(FCS) (less than 1%) in spinner flasks. 29 Cell culture super-
natants were pre-filtered, purified by affinity chromatography
using a protein G-Sepharose column, dialyzed against phos-
phate-buffered saline (PBS) and subsequently filtered through
0.45-μm. Purified antibodies for in vivo use were stored fro-
zen in PBS at a concentration of 1 mg/ml. Mouse IgG2a (clone
MG2a-53) and rat IgG2b (RTK4530) were used as isotype
control mAbs for in vivo use.
We established four different groups according to the
following experimental set up: Group I: Isotype control, mix-
ture of mouse IgG2a and rat IgG2b; Group II: Selective abla-
tion of mouse NK cells with anti-NK1.1 mAb (clone PK136);
Group III: Depletion of CD8 T cells with anti-CD8 mAb
(clone 2.43) and Group IV: depletion of CD8 T cells and
NK cells with anti-CD8 plus anti-NK1.1 mAb. All groups
received 1 mg intraperitoneally of each mAb at the time of
transplantation and at day 7 post-transplantation.
Antibodies for flow cytometry
The following list of flow cytometry antibodies were used for
the staining of axillary and brachial non-draining and draining
peripheral lymph node cell suspensions: CD3 (145-2C11, cat.
#100,321), CD49b (DX5, cat. #108,908), CD8 (53–6.7, cat.
#100,708), CD4 (GK1.5, cat. #100,432), CD62L (MEL-14, cat.
#104,421), CD44 (IM7, cat. #103,030), CD335 (NKp46, 29A1.4,
cat. #137,616)52, B220 (RA3-6B2, cat. #103,206), CXCR5
(L138D7, cat. #145,504) and PD-1 (29F.1A12, cat. #135,218)
mAbs were obtained from Biolegend. T and B activation anti-
gen (GL7, cat. # 562,967) and Fas (15A7, cat. # 17–0951-82)
were purchased from BD Biosciences and Thermo Fisher
Scientific, respectively. All antibodies used in this study were
properly titrated to determine optimal dilution to stain 0.5–
1 × 106 cells per tube. Fc receptors were blocked by pre-
incubating cell suspensions with 2 μg/ml of blocking anti-
FcγR mAb (2.4G2) was produced and purified in house and
used to reduce nonspecific binding before adding the specified
biotin- or fluorochrome-labeled mAbs.53 Biotinylated antibo-
dies were detected with SA-Brilliant Violet 421. Dead cells and
debris were excluded from acquisition by propidium iodide
(PI). Flow cytometry acquisition was carried out on a Cyan 9
cytometer (Beckman Coulter, Miami, FL, USA) and data ana-
lysis was performed using WinList version 8.0 (Verity Software
House, Topsham, ME, USA).
Allogeneic skin graft transplantation
Skin graft transplantation was performed following the pro-
tocol previously reported. 54,55 Briefly, skin graft beds were
prepared on the right lateral side of the thorax in the vicinity
of the right axillary/brachial draining lymph nodes region of
B6 recipient mice under ketamine-xylazine anesthesia. bm1
tail skin grafts were placed with four stitches and covered with
terramycin ointment impregnated gauze, which was removed
on day 8 post-transplantation (post-Tx). Signs of onset and
progression of rejection, such as dryness, loss of hair, con-
traction, scaling, and necrosis were recorded by visual inspec-
tion for a period of time of 40 days, every day in the first
20 days and then every other day from day 20 to day 40 after
transplantation. Skin grafts were considered fully rejected
when complete necrosis of the skin graft was observed.
Host anti-donor specific antibody response
For the measurement of B6 host anti-donor Kbm1 humoral
immune response, serum samples were collected from the
different experimental groups at day 13 and 21 after bm1
skin grafting, then diluted at (1:10) and incubated for 1
hour with 0.5 × 106 donor type thymocytes. The extent of
the host anti-donor isotype-specific humoral immune
response was determined by evaluating the mean fluorescence
intensity values of the staining. As positive control, Balb/c
skin grafts were placed on B6 recipients and the presence of
host anti-donor antibodies was measured at day 13 after
transplantation.
Gm-csf-mediated bone marrow-derived dendritic cell
differentiation
Syngeneic C57BL/6 (B6) and allogeneic bm1 bone marrow
cells were harvested from tibiae and differentiated with
30 ng/ml murine GM-CSF (PeproTech), as previously
described.56,57 Bone marrow-derived DC (BM-DC) were
finally matured upon overnight exposure to 1 µg/ml LPS
O111:B4 (Sigma-Aldrich).
Cd107a degranulation assay
1.5 × 105 of draining and non-draining (axillar and brachial)
pLNs were isolated around day of rejection from B6 syngeneic
or allogeneic bm1 skin grafted mice treated either with isotype
control or anti-NK1.1 antibody and then were re-stimulated
in vitro with 0.5 × 105 of either syngeneic (B6) or allogeneic
bm1 mature BM-DC. PE-labelled isotype-matched control
(clone Rtk-275, Biolegend) or PE-conjugated anti-CD107a
mAb (clone 1D4B, Biolegend) were added to the cell culture
and incubated for 1 hour at 37 ºC in 5% CO2 atmosphere.
Stimulator and responder cells were incubated for four addi-
tional hours in the presence of Golgi plug 2 μM monensin and
CD107a degranulation assay was used as a surrogate assay to
monitor cytolytic function on donor CD8+ T cells. 30 For the
gating strategy, a dump channel was set to include the follow-
ing markers (CD19, CD11b and CD11c).
In vivo cytotoxic t lymphocyte (CTL) assay
Single-cell suspensions were prepared from spleens of bm1
female mice in RPMI 1640 complete medium as target cells
for the in vivo CTL assay. Target cells were washed twice in
D-PBS and labeled with CFSE (Molecular Probes) at 1 μM for
10 min at 37°C. 58 The reaction was stopped by adding two
volumes of cold RPMI 1640 containing 10% FCS followed by
two washes in D-PBS. 15 × 106 of CFSE-labeled bm1 target
cells were i.v. injected to each group of mice at day 13 and day
21 post-skin graft transplantation. 24 hours later, recipient
mice were euthanized and the specific killing of bm1 target
cells was calculated as the absolute number of CFSE-labeled
MABS 1041
bm1 splenocytes remaining 24 hours after cell transfer in host
spleen and peripheral lymph nodes (pLNs).59
Histology
Allogeneic and syngeneic skin grafts samples from representa-
tive mice of each experimental group were fixed in 10% neutral-
buffered formalin and conventionally processed. Fixed samples
were dehydrated through a graded alcohol series before being
embedded in paraffin wax following conventional processing
for histological examination. Microtome Sections (4 µm thick)
were cut, mounted on glass microscope slides and stained with
hematoxylin and eosin. Finally, the slides were dehydrated and
mounted for histological examination.
Statistical analysis
Collected data was organized in excel worksheets and Prism
data tables. Results are expressed as mean ± SD or mean
± SEM. For the statistical analysis of normally distributed
data, statistical significance between non-draining versus
draining pLNs was calculated using two-tailed Student t test.
For the comparison of more than 2 groups, one way ANOVA
statistical test was applied. Adjustments for multiple compar-
isons were performed with the Tukey-Kramer comparison
test. These statistical studies were performed under the con-
ditions of independence of the data, normality test
(Kolmorogov test) and equal variances among groups
(Bartlett´s test). Parametric or non-parametric tests were
applied accordingly.
Skin graft survival was calculated by using the Kaplan–
Meier life table method and statistical analysis for the com-
parison of the survival curves was performed by the log rank
(Mantel-Cox) test. The statistical analysis was performed
using GraphPad Prism 6.0 software (Graphpad Software,
Inc., La Jolla, CA). A value of p < 0.05 was considered
statistically significant.
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CAV Cardiac allograft vasculopathy
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